TLR9 and urinary bladder cancer: Next, we set out to assess whether STAT3 inhibition/TLR9 stimulation using CpG-STAT3ASO will prove effective alone or together with immune checkpoint blockade against genitourinary cancers, such as Renca and MB49 tumors, two commonly used models of mouse kidney and bladder cancers (Figure 5A).